Aytekin Celep
Papers
1
Total Citations
35
H-Index
1
About
Aytekin Celep is a translational cancer researcher whose work focuses on malignant mesothelioma, a rare and aggressive cancer with limited treatment options. His major contributions center on improving therapeutic strategies through patient-derived models and ex vivo drug sensitivity testing. In his highly cited 2014 study, Celep characterized primary malignant mesothelioma cells isolated from pleural effusions and performed comprehensive drug sensitivity profiling. This work demonstrated the feasibility of using patient-derived cells to predict individual responses to chemotherapy, addressing the critical challenge that only 40% of patients respond to standard pemetrexed-platinum regimens. By establishing a method to assess chemosensitivity ex vivo, Celep’s research lays the groundwork for personalized treatment selection in mesothelioma, potentially sparing patients from ineffective therapies and their toxicities. His study has garnered 35 citations, reflecting its importance in the field of thoracic oncology and precision medicine. Through this foundational work, Celep has advanced the understanding of mesothelioma biology and opened new avenues for tailoring therapy to individual tumor profiles, offering hope for improved outcomes in this devastating disease.
Research Focus
Key Achievements
Top Papers
- 1